Nexalin's Insomnia Treatment Shows Significant Clinical Improvement, Brain-Network Effects in Peer-Reviewed Study
NXL sits 21% above its 52-week low of $0.33 on light trading volume (0.1× avg).
Summary
Nexalin Technology announced the publication of a peer-reviewed study in Psychotherapy and Psychosomatics, demonstrating statistically significant clinical improvement in chronic insomnia patients treated with its Deep Intracranial Frequency Stimulation (DIFS™) technology. The study also provided neuroimaging data highlighting measurable brain-network modulation. This positive scientific validation builds upon Nexalin's recent progress in its FDA strategy and the initiation of a pivotal clinical trial for its HALO™ Clarity device, which targets insomnia. For a micro-cap company like Nexalin, which is currently facing a "going concern" warning and Nasdaq delisting threat, this peer-reviewed data is a highly material positive catalyst. It significantly enhances the credibility of its proprietary technology and strengthens the investment thesis by supporting the potential for future regulatory approvals and commercialization. Investors will closely monitor the progress of the HALO™ Clarity pivotal trial and subsequent FDA submission, as this publication provides strong foundational support for the technology's efficacy and mechanism of action.
At the time of this announcement, NXL was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $0.33 to $2.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.